XML 26 R22.htm IDEA: XBRL DOCUMENT v3.19.3
Major Customers, Partnerships and Strategic Alliances (Tables)
9 Months Ended
Sep. 30, 2019
Kite Pharma Inc  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Revenues Recognized under Agreement
Revenues recognized under the agreement for the three and nine months ended September 30, 2019 and 2018 were as follows (in thousands):
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Revenue related to Kite agreement:
 
 
 
 
 
 
 
Recognition of license and stand-ready fee
$
6,296

 
$
6,296

 
$
18,682

 
$
12,249

Research services
2,565

 
2,732

 
7,551

 
4,295

Total
$
8,861

 
$
9,028

 
$
26,233

 
$
16,544


Pfizer SB-525  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Revenues Recognized under Agreement
Revenues recognized under the agreement for the three and nine months ended September 30, 2019 and 2018 were as follows (in thousands):
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Recognition of upfront fee related to Pfizer SB-525 agreement
$
3,440

 
$
10,421

 
$
5,035

 
$
26,262


Pfizer  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Revenues Recognized under Agreement
Revenues recognized under the agreement for the three and nine months ended September 30, 2019 and 2018 were as follows (in thousands):
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Recognition of upfront fee related to Pfizer C9ORF72 agreement
$
468

 
$
394

 
$
1,538

 
$
1,470


Sanofi  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Revenues Recognized under Agreement
Revenues recognized under the agreement, excluding the milestone revenue, for the three and nine months ended September 30, 2019 and 2018 were as follows (in thousands):
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Revenue related to Sanofi agreement:
 
 
 
 
 
 
 
Recognition of upfront fee
$
940

 
$
1,094

 
$
2,594

 
$
3,432

Research services
1,814

 
1,146

 
5,169

 
7,707

Total
$
2,754

 
$
2,240

 
$
7,763

 
$
11,139